TSX runs higher on rate cut expectations
Investing.com - Jefferies raised its price target on Regeneron Pharmaceuticals (NASDAQ:REGN) to $831.00 from $813.00 on Wednesday, while maintaining a Buy rating on the stock. The biotech giant, currently valued at $60.8 billion, trades at a P/E ratio of 14, with InvestingPro data showing 11 analysts recently revising earnings estimates upward.
The price target increase follows positive topline data from Regeneron’s Phase 3 NIMBLE trial testing cemdisiran with and without pozelimab in generalized Myasthenia Gravis (gMG) patients.
According to the data, cemdisiran monotherapy demonstrated a placebo-adjusted MG-ADL change of -2.3 at week 24, which Jefferies notes is competitive compared to C5 therapies like Soliris and Ultomiris that showed changes of 1.7-1.9.
The trial results showed no increases in infection rates and highlighted a favorable quarterly dosed healthcare provider-administered subcutaneous formulation, positioning cemdisiran as a potential next-best option after Vyvgart in the growing gMG market.
Based on these results, Jefferies increased its peak sales estimate for cemdisiran in gMG to $1.05 billion, driving the price target adjustment from $813 to $831.
In other recent news, Regeneron Pharmaceuticals reported promising results from its Phase 3 trial for cemdisiran, an investigational drug for generalized myasthenia gravis. The trial demonstrated a significant improvement in the Myasthenia Gravis Activities of Daily Living score, exceeding results from existing therapies. Additionally, Truist Securities adjusted its price target for Regeneron to $812, citing concerns about Eylea, although the company exceeded expectations in its second-quarter 2025 earnings due to strong performance from Dupixent and Libtayo. Rothschild Redburn initiated coverage with a Buy rating and a $890 price target, highlighting the company’s growth potential. TD Cowen maintained its Buy rating and $780 price target, expressing confidence in Regeneron’s pipeline, especially its allergy programs. Cantor Fitzgerald also reiterated its Overweight rating with a $678 price target, noting positive developments with Eylea HD despite some regulatory setbacks. These recent developments reflect a mix of optimism and caution among analysts regarding Regeneron’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.